奥扎格雷-脑得生序贯治疗急性脑梗死的前瞻性药物经济学研究  

Study of the drug pharmacoeconomics on the sequntial antimicrobial therapy of the ozagrel- Naodesheng capsule in the treatment of acute cerebral infarction

作　　者：王玉和[1] 余昌胤[2] 张骏[2] 雷显泽[2] 余娜[2] 周妮[2] 

机构地区：[1]遵义医学院药学院药剂教研室,贵州遵义563003 [2]遵义医学院附属医院神经内科,贵州遵义563003

出　　处：《中国临床药理学杂志》2014年第2期137-139,共3页The Chinese Journal of Clinical Pharmacology

基　　金：贵州省卫生厅科学技术基金资助项目(D-234)

摘　　要：目的观察奥扎格雷-脑得生序贯治疗急性脑梗死的疗效与安全性,并对其进行药物经济学评价。方法前瞻性的随机双盲对照临床研究,2组均为132例急性脑梗死患者,试验组用奥扎格雷80 mg,ivgtt,bid,14 d后改用脑得生6粒,po tid;对照组用奥扎格雷80 mg,ivgtt,bid,均28 d。用药物经济学的最小成本分析法和成本—效果分析法进行评价。结果 2组临床疗效相近,以临床总有效率计C/E分别为141.8和205.4;ΔC/ΔE为894000。结论 2组费用差异有统计学意义;序贯治疗组更具成本—效果优势。Objective To study of the drug pharmacoeconomics on the sequntial antimicrobial therapy of the ozagrel - Naodesheng capsule in the treatment of acute cerebral infarction. Methods It used prospective randomized doulbe - blind controlled design, the 132 samples of the trim group was administered with Ozagrel 80 mg twice a day. After fourteen days Naodesheng capsule was taken in 14 days, 6 pills each time, third times per day. The patients in control group was administered with oza- grel 80 mg twice a day for 28 days. The pharmacoeeonomics of minimum cost analysis and cost -effectiveness were used to analyze. Results The clinic curative effect of two group was intimate. The clinic total effective rate counting C/E was respectively 141.8 and 205.4. hE/hE was 894000. Conclusion There was significant difference in the cost in two groups. The cost - effect of sequntial antimicrobial therapy in curing a- cute cerebral infarction was more excellent.

关 键 词：急性脑梗死 奥扎格雷 脑得生胶囊 序贯治疗 药物经济学 最小成本分析法 成本-效果分析法 

分 类 号：R954[医药卫生—药学] R943.3